You are here

Publications

Found 370 results
Author [ Title(Desc)] Type Year
Filters: First Letter Of Last Name is L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
T
Lee JJin, Lee S-K, Song N, Nathan TO, Swarts BM, Eum S-Y, Ehrt S, Cho S-N, Eoh H.  2019.  Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in Mycobacterium tuberculosis.. Nat Commun. 10(1):2928.
Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L et al..  1998.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis.. Immunity. 9(1):25-34.
Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L et al..  1998.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis.. Immunity. 9(1):25-34.
Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L et al..  1998.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis.. Immunity. 9(1):25-34.
Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L et al..  1998.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis.. Immunity. 9(1):25-34.
Elkon KB, Liu CC, Gall JG, Trevejo J, Marino MW, Abrahamsen KA, Song X, Zhou JL, Old LJ, Crystal RG et al..  1997.  Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors.. Proc Natl Acad Sci U S A. 94(18):9814-9.
Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP.  2009.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.. PLoS Pathog. 5(8):e1000548.
Zhang L, Jiang X, Pfau D, Ling Y, Nathan CF.  2021.  Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death.. J Exp Med. 218(2)